Company: TBPH
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001104659-25-033819
Chunk: 68

Company: Theravance Biopharma, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 68
---
 ​ | ​ | ​ | ​    | $ | -182,101 | ​ | ​ |
| Compensation Actually Paid                                                                                                                                                                | ​ | ​ | ​    | $ | 1,080,541 | ​ | ​ | ​ | ​    | $ | 1,514,466 | ​ | ​ | ​ | ​    | $ |  789,294 | ​ | ​ |

(1)

Cumulative total shareholder return on our ordinary shares from December 31, 2021 through December 31, 2022, December 31, 2023, and December 31, 2024, respectively. Assumes the investment of $100 on December 31, 2021 in the NASDAQ Biotechnology Index and assumes the reinvestment of dividends.

​

(2)

The dollar amounts reported represent the amount of net income reflected in our audited financial statements for the applicable year.

Narrative Disclosure Our compensation committee makes executive compensation decisions in consultation with our compensation consultant based on a number of factors, including, without limitation, market conditions,

42

TABLE OF CONTENTS individual NEO performance and experience, targeted executive retention efforts in connection with our restructuring, and incentivizing achievement of long-term drug development and commercialization goals. Compensation Actually Paid and Total Shareholder Return The following graph reflects the relationship between the PEO and average non-PEO NEO “compensation actually paid” (“CAP”), total compensation from the Summary Compensation Table (“SCT”) and our cumulative Total Shareholder Return (“TSR”), assuming an initial fixed investment on December 31, 2021 of $100, for the fiscal years ended December 31, 2024, 2023 and 2022. In addition, the SCT total compensation of our PEO and the average SCT total compensation for our non-PEO NEOs, each as disclosed in the table above, are included in the following graph as supplemental disclosures for each of the periods presented. Compensation Actually Paid and Net Income The following graph reflects the relationship between the PEO and average non-PEO NEO CAP, total compensation from the SCT and our net income (loss) for the fiscal years ended December 31, 2024, 2023 and 2022. While we are required by the SEC rules to disclose the relationship between our net income and “compensation actually paid” to our NEOs, this is not a metric our compensation committee currently uses in evaluating our NEOs’ compensation. In addition, the SCT total compensation of our PEO and